THERAPY DOSSIER · th-9cb00a73caa4

Low-power laser, InGaAlP, 670 nm, 30 mW

Device · Device (low-power laser / photobiomodulation); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Device (low-power laser / photobiomodulation); not a ChEMBL entity
Target: Not recorded
Injury models: Fracture
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07296068 ↗NAnot yet recruiting

Acute Photobiomodulation to Improve Balance and Cognition in Ataxia

Ataxia

Enrolment: 20 · Results not recorded

NCT06145867 ↗NAunknown

Photobiomodulation Therapy in Myalgic Encephalomyelitis

Myalgic Encephalomyelitis

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22850224 ↗2012Reported benefit

Low-power laser therapy for repairing acute and chronic-phase bone lesions.

RatFractureUnspecifiedWistarMalen = 63 adult male rats in nine groups; subgroups of n = 7 analy…Transcutaneous irradiation over the bone lesion90 J/cm2Treatment started in either the acute phase or the chronic phase of the bone in…

Model: Surgically created bone lesion (osteotomy), assessed on days 9, 17 and 28 after surgery

Animals treated in the acute phase showed a more extensive endochondral ossification process. Laser-treated animals had significantly increased serum alkaline phosphatase and a gradual increase in bone stiffness. Effects were more prominent when treatment began during the acute phase.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…